인간 안티트롬빈 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2024-2032년)

Growth Factors of human antithrombin Market

The global human antithrombin market is witnessing steady growth due to rising clinical awareness, increasing prevalence of rare coagulation disorders, and expanding applications in surgical and intensive care settings. According to the latest industry insights, the market was valued at USD 367.1 million in 2024, is projected to reach USD 381.3 million in 2025, and is expected to grow to USD 512.0 million by 2032, reflecting a CAGR of 4.3% during the forecast period. In 2024, Europe dominated the market with a 43.28% share, attributed to the strong presence of established players, well-developed healthcare infrastructure, and wide availability of plasma-derived antithrombin products.

Human antithrombin, a glycoprotein derived from human plasma, plays a crucial role in inactivating thrombin and other serine proteases, preventing abnormal blood clotting. The growing adoption of antithrombin concentrates in surgical procedures, cardiac surgeries, organ transplants, and Extracorporeal Membrane Oxygenation (ECMO) treatments drives market expansion. Additionally, increasing prevalence of hereditary antithrombin deficiency, disseminated intravascular coagulation (DIC), and thrombophilia further fuels global demand for antithrombin supplementation.

Major market players include CSL, Octapharma AG, Grifols S.A., Kedrion S.p.A., and Takeda Pharmaceutical Company Limited, all of which benefit from strong regional presence and established product portfolios in plasma fractionated products. Their ongoing innovations and strategic expansions continue to support the market growth.

Market Drivers and Opportunities

The primary driver of the human antithrombin market is increasing usage in therapeutic applications. Hereditary antithrombin deficiency affects roughly 0.02% to 0.05% of the global population, translating to thousands of patients requiring lifelong supplementation. Antithrombin concentrates are especially critical in managing patients undergoing cardiac surgeries. For instance, in June 2024, the Annals of Thoracic Surgery Short Reports highlighted that the annual average cardiac surgery volume in the U.S. was 271.5 per 100,000 population, emphasizing the clinical reliance on antithrombin therapies.

Moreover, combination therapies with heparin provide synergistic anticoagulant effects, presenting new avenues for market growth. Such therapies are increasingly incorporated in clinical protocols to enhance therapeutic outcomes in patients with heparin resistance or complex coagulopathies.

Market Restraints and Challenges

Despite its clinical importance, the market faces constraints due to plasma-derived antithrombin safety concerns, including allergic reactions, hemorrhage risk, and potential exposure to infectious agents. High doses, particularly during severe sepsis or when co-administered with heparin, may increase bleeding risks, limiting adoption in certain patient populations.

Additionally, the market is challenged by complex regulatory frameworks and inconsistent reimbursement scenarios, particularly in low- and middle-income countries. Lengthy approval processes, strict safety regulations, and limited insurance coverage hinder widespread adoption and slow commercialization of new products.

Market Trends

Recent trends indicate the expansion of antithrombin applications beyond hereditary deficiencies. In Japan, antithrombin is part of standard care for septic patients with DIC, with approved doses reaching 1,500 IU/day, demonstrating the therapeutic versatility of these products. Moreover, hospitals and clinics continue to lead end-user adoption due to the clinical demand for anticoagulants during surgical procedures, while pharmaceutical and biotechnology industries are increasing research and diagnostic applications.

Segmentation Analysis

• By Application: The therapeutic segment held the largest market share in 2024 due to widespread use in surgeries and heparin-resistant patients. Research and diagnostic applications are growing but at a slower pace.
• By Dosage Form: Lyophilized powders dominate owing to enhanced stability and ease of handling, used in products such as Thrombotrol VF (CSL) and THROMBATE III (Grifols). Liquid formulations account for minimal market share.
• By End User: Hospitals and clinics represent the largest end-user segment due to the direct administration of antithrombin in therapeutic procedures.

Regional Outlook

• Europe: Leading region with USD 158.9 million in 2024, supported by a strong network of plasma fractionation centers and government initiatives like France 2030, which promote local biologics production.
• Asia Pacific: Fastest-growing region due to rising congenital antithrombin deficiency awareness and expanding plasma production infrastructure.
• North America: Limited share due to stringent regulatory hurdles for plasma-derived products.
• Rest of the World: Includes Latin America and Middle East & Africa, with slower adoption owing to limited product penetration and infrastructure constraints.

Competitive Landscape

The market is semi-consolidated, with CSL, Grifols S.A., Kedrion S.p.A., and Octapharma AG dominating. These companies leverage extensive product portfolios, manufacturing capabilities, and strategic collaborations to maintain leadership. Other global participants include Takeda Pharmaceutical Company Limited and Medix Biochemica, focusing on expanding antithrombin applications and research collaborations.

Conclusion

With a market value of USD 367.1 million in 2024, rising to USD 381.3 million in 2025, and projected to reach USD 512.0 million by 2032, the global human antithrombin market is poised for steady growth. Key drivers include therapeutic demand in surgeries, combination therapies, and rising awareness of coagulation disorders, while challenges such as safety concerns and regulatory barriers persist. Ongoing research, expansion in Asia Pacific, and innovative product launches are expected to shape the market trajectory through 2032.

Segmentation By Application

• Therapeutic
• Research & Diagnostic

By Dosage Form

• Lyophilized Powder
• Liquid

By End User

• Hospitals & Clinics
• Pharmaceutical & Biotechnology Industry
• Research Institutes

By Region

• North America (By Application, Dosage Form, End User, and Country/Sub-Region)
  • U.S.
  • Canada
• Europe (By Application, Dosage Form, End User, and Country/Sub-Region)
  • Germany
  • France
  • U.K.
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Application, Dosage Form, End User, and Country/Sub-Region)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Southeast Asia
  • Rest of the Asia Pacific
• Rest of the World (By Application, Dosage Form, and End User)

Table of Content

1. Introduction

• 1.1. Market Scope
• 1.2. Market Segmentation
• 1.3. Market Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Cardiovascolar Diseases, By Key Countries
• 4.2. Regolatory Scenario, By Key Countries
• 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Approvals, Launches etc.)

5. Global Human Antithrombin Market Analysis, Insights and Forecast, 2019-2032

• 5.1. Market Analysis, Insights and Forecast - By Application
  • 5.1.1. Therapeutic
  • 5.1.2. Research & Diagnostic
• 5.2. Market Analysis, Insights and Forecast - By Dosage Form
  • 5.2.1. Lyophilized Powder
  • 5.2.2. Liquid
• 5.3. Market Analysis, Insights and Forecast - By End User
  • 5.3.1. Hospitals & Clinics
  • 5.3.2. Pharmaceutical & Biotechnology Industry
  • 5.3.3. Research Institutes
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Rest of the World

6. North America Human Antithrombin Market Analysis, Insights and Forecast, 2019-2032

• 6.1. Market Analysis, Insights and Forecast - By Application
  • 6.1.1. Therapeutic
  • 6.1.2. Research & Diagnostic
• 6.2. Market Analysis, Insights and Forecast - By Dosage Form
  • 6.2.1. Lyophilized Powder
  • 6.2.2. Liquid
• 6.3. Market Analysis, Insights and Forecast - By End User
  • 6.3.1. Hospitals & Clinics
  • 6.3.2. Pharmaceutical & Biotechnology Industry
  • 6.3.3. Research Institutes
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Human Antithrombin Market Analysis, Insights and Forecast, 2019-2032

• 7.1. Market Analysis, Insights and Forecast - By Application
  • 7.1.1. Therapeutic
  • 7.1.2. Research & Diagnostic
• 7.2. Market Analysis, Insights and Forecast - By Dosage Form
  • 7.2.1. Lyophilized Powder
  • 7.2.2. Liquid
• 7.3. Market Analysis, Insights and Forecast - By End User
  • 7.3.1. Hospitals & Clinics
  • 7.3.2. Pharmaceutical & Biotechnology Industry
  • 7.3.3. Research Institutes
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. Germany
  • 7.4.2. UK
  • 7.4.3. France
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Human Antithrombin Market Analysis, Insights and Forecast, 2019-2032

• 8.1. Market Analysis, Insights and Forecast - By Application
  • 8.1.1. Therapeutic
  • 8.1.2. Research & Diagnostic
• 8.2. Market Analysis, Insights and Forecast - By Dosage Form
  • 8.2.1. Lyophilized Powder
  • 8.2.2. Liquid
• 8.3. Market Analysis, Insights and Forecast - By End User
  • 8.3.1. Hospitals & Clinics
  • 8.3.2. Pharmaceutical & Biotechnology Industry
  • 8.3.3. Research Institutes
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. South Korea
  • 8.4.6. Southeast Asia
  • 8.4.7. Rest of Asia Pacific

9. Rest of World Human Antithrombin Market Analysis, Insights and Forecast, 2019-2032

• 9.1. Market Analysis, Insights and Forecast - By Application
  • 9.1.1. Therapeutic
  • 9.1.2. Research & Diagnostic
• 9.2. Market Analysis, Insights and Forecast - By Dosage Form
  • 9.2.1. Lyophilized Powder
  • 9.2.2. Liquid
• 9.3. Market Analysis, Insights and Forecast - By End User
  • 9.3.1. Hospitals & Clinics
  • 9.3.2. Pharmaceutical & Biotechnology Industry
  • 9.3.3. Research Institutes

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2024)
• 10.2. Company Profiles
  • 10.2.1. CSL
    • 10.2.1.1. Overview
    • 10.2.1.2. Products
    • 10.2.1.3. Financials (Based on Availability)
    • 10.2.1.4. Recent Developments
    • 10.2.1.5. Strategies
    • 10.2.1.6. SWOT,Etc.
  • 10.2.2. Octapharma AG
    • 10.2.2.1. Overview
    • 10.2.2.2. Products
    • 10.2.2.3. Financials (Based on Availability)
    • 10.2.2.4. Recent Developments
    • 10.2.2.5. Strategies
    • 10.2.2.6. SWOT,Etc.
  • 10.2.3. Takeda Pharmaceutical Company Limited
    • 10.2.3.1. Overview
    • 10.2.3.2. Products
    • 10.2.3.3. Financials (Based on Availability)
    • 10.2.3.4. Recent Developments
    • 10.2.3.5. Strategies
    • 10.2.3.6. SWOT,Etc.
  • 10.2.4. Grifols, S.A.
    • 10.2.4.1. Overview
    • 10.2.4.2. Products
    • 10.2.4.3. Financials (Based on Availability)
    • 10.2.4.4. Recent Developments
    • 10.2.4.5. Strategies
    • 10.2.4.6. SWOT,Etc.
  • 10.2.5. Medix Biochemica
    • 10.2.5.1. Overview
    • 10.2.5.2. Products
    • 10.2.5.3. Financials (Based on Availability)
    • 10.2.5.4. Recent Developments
    • 10.2.5.5. Strategies
    • 10.2.5.6. SWOT,Etc.
  • 10.2.6. Kedrion S.p.A.
    • 10.2.6.1. Overview
    • 10.2.6.2. Products
    • 10.2.6.3. Financials (Based on Availability)
    • 10.2.6.4. Recent Developments
    • 10.2.6.5. Strategies
    • 10.2.6.6. SWOT,Etc.
  • 10.2.7. Scripps Laboratories
    • 10.2.7.1. Overview
    • 10.2.7.2. Products
    • 10.2.7.3. Financials (Based on Availability)
    • 10.2.7.4. Recent Developments
    • 10.2.7.5. Strategies
    • 10.2.7.6. SWOT,Etc.